{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:36:08Z","timestamp":1788456968614,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jcyt.2025.102028","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:57:30Z","timestamp":1764662250000},"page":"102028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-992X","authenticated-orcid":false,"given":"Tong-Yoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8089-3800","authenticated-orcid":false,"given":"Kyoung Il","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngwoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-126X","authenticated-orcid":false,"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102028_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0003","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.102028_bib0004","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.18724","article-title":"How I treat refractory\/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells","volume":"201","author":"Nagler","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0006","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102028_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0008","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0009","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2022.07.015","article-title":"Chimeric antigen receptor T cell therapy versus hematopoietic stem cell transplantation: an evolving perspective","volume":"28","author":"Goldsmith","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102028_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41409-023-01949-x","article-title":"Role of allogeneic hematopoietic cell transplant for relapsed\/refractory aggressive B-cell lymphomas in the CART era","volume":"58","author":"Mussetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0011","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2025.102028_bib0012","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102028_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0014","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102028_bib0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0016","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0017","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44241-0","article-title":"The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed\/refractory diffuse large B cell lymphoma","volume":"13","author":"Min","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2025.102028_bib0019","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/sam.11539","article-title":"Survival trees based on heterogeneity in time-to-event and censoring distributions using parameter instability test","volume":"14","author":"Kundu","year":"2021","journal-title":"Statistical Analysis"},{"key":"10.1016\/j.jcyt.2025.102028_bib0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12185-024-03888-9","article-title":"Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R\/R LBCL and poor prognostic factors","volume":"121","author":"Hayashino","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0021","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood.2021011867","article-title":"Graft-versus-host disease: a disorder of tissue regeneration and repair","volume":"138","author":"Chakraverty","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102028_bib0022","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102028_bib0023","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0024","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41409-022-01903-3","article-title":"Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory\/relapsed B-cell lymphoma","volume":"58","author":"Yang","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102028_bib0026","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2023-186510","article-title":"Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: response and survival are significantly superior in female compared to male patients","volume":"142","author":"Buecklein","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102028_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70831","article-title":"Sex differences in outcomes of Chimeric Antigen Receptor (CAR) T-cell therapy","volume":"14","author":"Tan","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0028","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.102028_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2025.102028_bib0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102028_bib0031","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102028_bib0032","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41409-023-01965-x","article-title":"Fludarabine\/TBI 8 Gy versus fludarabine\/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT","volume":"58","author":"Bug","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102028_bib0033","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:57:34Z","timestamp":1773392254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1465324925009247"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102028","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102028"}}